Huibang biological was established in May 2013. It is a professional medical device manufacturer integrating R & D, production, sales and after-sales, with a complete industrial chain. It is also a large-scale IVD (in vitro diagnostic reagent) R & D and manufacturing enterprise in Anhui Province. There are three core technology platforms: IVD (in vitro diagnostic reagents) industrialization platform, medical device manufacturing platform, biological raw materials/scientific research results transformation platform. The main directions are maternal and child health care, chronic diseases, tumors and cardiovascular in vitro diagnostic reagents, medical laboratory instruments and biological raw materials/scientific research results transformation platform.

Since its establishment, the company has achieved"High-tech Enterprise Certificate”、“The 6th China Innovation and Entrepreneurship Competition Award”、“New R & D Institutions in Anhui Province”、“Gold Award for Innovative Products in In Vitro Diagnostics Industry”、“51 patents, including 17 invention patents”、“16 Exclusive Product Registration Certificates"Wait.

The company currently employs 150 people, and the talent team has successively achieved"the People's Republic of China State Council Special Allowance”、“Top 10 Most Influential Research Award for Diabetes Research in China”、“Second Prize of Huaxia Medical Science and Technology Award”、“Second Prize of Chinese Medical Science and Technology Award”、“National Key R & D Project (2017YFC0909600)”、“National Natural Science Foundation of China (81561128015)”、“Second Prize of Science and Technology Progress Award of Ministry of Education"Wait.

The company is now located at No. 18 Diving East Road, High-tech Zone, with more than 3000 square meters of IVD 100,000-class purification workshop and office space, and more than 1000 square meters of monoclonal antibody research and development and preparation center. In August 2022, the company started construction of the Huibang Bio-Industrial Park project (No. 88 Peacock Tai Road), and improved the Huibang IVD (in vitro diagnostic reagents) industrial chain format. The project land is 40 mu, with a total investment of 0.45 billion yuan.

With the support of the government and all walks of life, Huibang Bio has won many awards, of which 2021"Non-invasive Detection System for Diabetic Nephropathy" Elected Gold Award for Outstanding Innovative Products in Vitro Diagnosis in China; Hefei High-tech Zone "Deep Science and Technology" Enterprise in 2022; In 2022, the "Non-invasive Detection System for Diabetic Nephropathy" won the "International Advanced" level of scientific and technological achievements evaluation. In 2022, "Insulin-like Growth Factor Binding Protein -1/Fetal Fiberlink Protein Test Kit" was elected as the Gold Award for Outstanding Innovative Products in China in Vitro Diagnosis in Vitro; in 2023, "haptoglobin/urinary microalbumin/creatinine detection kit (dry method)" was included in the key cultivation varieties of Hefei biomedical industry; in 2023, the second prize of the National Ministry of Education Science and Technology Progress Award.

Huibang Biology practices medicine, establishes a strict and complete quality management system, adheres to the development model of production, education and research, and technological innovation to build an internationally competitive biomedical diagnostic reagent company.

The company's existing project technology platforms include: blood screening technology, liquid phase chemiluminescence platform technology, immune microfluidic technology, fluorescence immune POCT technology, monoclonal antibody preparation technology, bacterial culture prokaryotic expression technology, cell culture eukaryotic expression technology, dry biochemical rapid detection technology, tumor cell culture drug sensitivity test detection technology, in vitro diagnostic equipment development technology (optical sensing development technology, mechanical transmission development technology, integrated circuit control module development technology, biochemical immune joint instrument manufacturing technology, automation control development technology, software development), etc.

The company has raw materials such as ferritin, pepsinogen I, pepsinogen II, serum amyloid A and 3C protease (to be developed).